Alkermes: A Patient Long on CNS Upside and Optionality From Recent M&A
Alkermes trades like a commercial-stage CNS company with a sizable market cap ($7.7B), steady free cash flow (~$222M last reported) and an active pipeline. The stock sits below its 52-week high ($55.67) after a year of M&A and pipeline repositioning. I view ALKS as a long with a 180-trading-day horizon: the base business finances optionality, while…